Edition:
United States

Foundation Medicine Inc (FMI.OQ)

FMI.OQ on NASDAQ Stock Exchange Global Select Market

74.90USD
16 Feb 2018
Change (% chg)

$5.95 (+8.63%)
Prev Close
$68.95
Open
$69.15
Day's High
$74.95
Day's Low
$69.15
Volume
131,451
Avg. Vol
81,067
52-wk High
$75.05
52-wk Low
$22.40

Latest Key Developments (Source: Significant Developments)

Foundation Medicine, Pfizer Announce Partnership To Develop Companion Diagnostics For Pfizer’S Oncology Portfolio
Tuesday, 16 Jan 2018 07:00am EST 

Jan 16 (Reuters) - Foundation Medicine Inc ::FOUNDATION MEDICINE AND PFIZER ANNOUNCE BROAD PARTNERSHIP TO DEVELOP COMPANION DIAGNOSTICS FOR PFIZER’S ONCOLOGY PORTFOLIO.FOUNDATION MEDICINE - PARTNERSHIP FOCUSES ON DEVELOPMENT, REGULATORY SUPPORT AND COMMERCIALIZATION OF COMPANION DIAGNOSTICS.FOUNDATION MEDICINE - CENTERS FOR MEDICARE & MEDICAID SERVICES ISSUED PRELIMINARY NATIONAL COVERAGE DETERMINATION FOR FOUNDATIONONE CDX.FOUNDATION MEDICINE INC - FINAL POLICY FOR FOUNDATIONONE CDX IS EXPECTED TO ISSUE DURING Q1 OF 2018.  Full Article

Foundation Medicine Reports Preliminary 2017 Results
Monday, 8 Jan 2018 06:30am EST 

Jan 8 (Reuters) - Foundation Medicine Inc ::FOUNDATION MEDICINE REPORTS PRELIMINARY 2017 RESULTS.- ‍ PRELIMINARY 2017 TOTAL REVENUE OF APPROXIMATELY $152.9 MILLION, A 31% YEAR OVER YEAR INCREASE​.- ‍ PRELIMINARY UNAUDITED TOTAL REVENUE OF APPROXIMATELY $48.9 MILLION FOR Q4 OF 2017​.Q4 REVENUE VIEW $39.2 MILLION -- THOMSON REUTERS I/B/E/S.FY2017 REVENUE VIEW $142.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Foundation Medicine Q3 loss per share $0.90
Wednesday, 1 Nov 2017 04:01pm EDT 

Nov 1 (Reuters) - Foundation Medicine Inc :Foundation Medicine announces 2017 third quarter results and recent highlights.Q3 loss per share $0.90.Sees FY 2017 revenue $135 million to $145 million.Q3 revenue $42.7 million versus I/B/E/S view $38 million.Q3 earnings per share view $-1.10 -- Thomson Reuters I/B/E/S.  Full Article

Foundation Medicine receives approval from state of New York for foundation act liquid biopsy assay
Monday, 2 Oct 2017 07:00am EDT 

Oct 2 (Reuters) - Foundation Medicine Inc : :Foundation Medicine Inc - receives approval from state of New York for foundation act liquid biopsy assay.  Full Article

Foundation Medicine and Roche enters into a fifth amendment to Collaboration Agreement
Wednesday, 13 Sep 2017 04:49pm EDT 

Sept 13 (Reuters) - Foundation Medicine Inc :Foundation Medicine Inc - On September 8, company and Roche entered into a fifth amendment to Collaboration Agreement - SEC filing.Foundation Medicine Inc- Amendment reduced certain exclusivity provisions relating to blood-based tumor mutational burden assays.  Full Article

Foundation Medicine entered into amendment letter agreement with Roche Finance
Tuesday, 1 Aug 2017 04:36pm EDT 

Aug 1 (Reuters) - Foundation Medicine Inc :Foundation Medicine Inc - co entered into amendment letter agreement with Roche Finance Ltd amending credit facility agreement, dated August 2, 2016.Foundation Medicine - amendment amends existing credit facility to provide for extension of period during which co may borrow funds from 3 to 4 yrs.Foundation Medicine Inc - amendment increases available funds from $100 million to $200 million - SEC filing.  Full Article

Foundation Medicine Q2 revenue $35 mln
Tuesday, 1 Aug 2017 04:01pm EDT 

Aug 1 (Reuters) - Foundation Medicine Inc :Foundation Medicine announces 2017 second quarter results and recent highlights.Q2 loss per share $1.24.Q2 revenue $35 million versus I/B/E/S view $34.9 million.Sees FY 2017 revenue $135 million to $145 million.Q2 earnings per share view $-1.11 -- Thomson Reuters I/B/E/S.Foundation Medicine Inc - company is increasing clinical volume guidance and now expects to deliver between 61,000 and 64,000 clinical tests in 2017.Foundation Medicine Inc - increasing operating expenses and now expects they will be in range of $215 million and $225 million for 2017.FY 2017 revenue view $138.2 million -- Thomson Reuters I/B/E/S.  Full Article

Kura Oncology ‍enters into collaboration agreement with Foundation Medicine ​
Thursday, 13 Jul 2017 07:30am EDT 

July 13 (Reuters) - Foundation Medicine Inc -:Kura Oncology Inc - ‍entered into a collaboration agreement with Foundation Medicine, Inc.​.Kura Oncology Inc - collaboration to support patient enrollment for co's clinical program for tipifarnib.  Full Article

Foundation Medicine announces Q1 revenue $26.3 million
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Foundation Medicine Inc :Foundation Medicine announces 2017 first quarter results and recent highlights.Q1 loss per share $1.31.Sees FY 2017 revenue $135 million to $145 million.Q1 revenue $26.3 million versus I/B/E/S view $29.1 million.Q1 earnings per share view $-1.01 -- Thomson Reuters I/B/E/S.Foundation Medicine Inc says Foundation Medicine's business and financial outlook for 2017 remains unchanged.  Full Article

Foundation Medicine Q4 loss per share $1.02
Wednesday, 22 Feb 2017 04:01pm EST 

Foundation Medicine Inc : Foundation Medicine announces 2016 fourth quarter and year-end results, recent highlights and 2017 outlook . Sees FY 2017 revenue $135 million to $145 million . Q4 revenue $28.8 million versus I/B/E/S view $29.2 million . Q4 loss per share $1.02 . Q4 earnings per share view $-0.96 -- Thomson Reuters I/B/E/S . Foundation Medicine Inc says company expects to deliver between 53,000 and 56,000 clinical tests in 2017 . Company expects operating expenses will be in range of $205 million to $215 million in 2017 .FY2017 revenue view $147.8 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Foundation Medicine, Pfizer Announce Partnership To Develop Companion Diagnostics For Pfizer’S Oncology Portfolio

* FOUNDATION MEDICINE AND PFIZER ANNOUNCE BROAD PARTNERSHIP TO DEVELOP COMPANION DIAGNOSTICS FOR PFIZER’S ONCOLOGY PORTFOLIO